Trial Profile
A poilot study of eribulin monotherapy in chemorefractory patients with BRAF V600E-mutant metastatic colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms BRAVE PILOT study
- 06 Jun 2018 Status changed from recruiting to discontinued.
- 08 Jun 2017 New trial record